Fate Therapeutics (FATE) Enterprise Value Growth (1y) (2013 - 2026)
Fate Therapeutics (FATE) Enterprise Value Growth (1y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Fate Therapeutics | 302.48 Mn | 302.48 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 27.29% |
| Dec 31, 2025 | 27.02% |
| Sep 30, 2025 | 27.45% |
| Jun 30, 2025 | 26.91% |
| Mar 31, 2025 | 37.31% |
| Dec 31, 2024 | 11.46% |
| Sep 30, 2024 | 15.10% |
| Jun 30, 2024 | 19.33% |
| Mar 31, 2024 | 6.20% |
| Dec 31, 2023 | 27.75% |
| Sep 30, 2023 | 30.76% |
| Jun 30, 2023 | 33.56% |
| Mar 31, 2023 | 28.74% |
| Dec 31, 2022 | 29.17% |
| Sep 30, 2022 | 25.57% |
| Jun 30, 2022 | 18.22% |
| Mar 31, 2022 | 27.38% |
| Dec 31, 2021 | -27.54% |
| Sep 30, 2021 | -38.85% |
| Jun 30, 2021 | -30.41% |